Bibliography
- Blanchette F, Neuhause O. Glatiramer acetate – evidence for a dual mechanism of action. J Neurol 2008;255(Suppl 1):25-36
- Thrower BW. Clinically isolated syndromes – predicting and delaying multiple sclerosis. Neurology 2007;68(Suppl 4):S12-5
- Kappos L, Polman CH, Freedman MS, Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9
- Kappos L, Freedman MS, Polman CH, Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-97
- Kappos L, Freedman MS, Edan G, Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the Phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-97
- Comi G, Martinelli V, Rodgeher M, Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-11
- Jacobs LD, Beck RW, Simon JH, Intramuscular interferon beta-1a therapy initiated during a first demyelination event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904
- Comi G, Filippi M, Barkhof F, Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82
- Johnson KP, Brooks BR, Cohen JA, Copolymer 1 reduced relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
- Durelli L, Verdum E, Barbero P, Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002;359:1453-60
- Hartung HP. High-dose, high-frequency recombinant interferon beta-1a in the treatment of multiple sclerosis. Expert Opin Pharmacother 2009;10:291-309
- Mikol DD, Barkhof F, Chang P, Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study); a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-14
- Phase IV, rater-blinded, randomized study, comparing the effects of 0.25 mg of betaseron with 20 mg of copaxone in patients with relapsing-remitting or clinically isolated forms of multiple sclerosis using 3 Tesla MRI with triple-dose gadolinium. Available from: http://clinicaltrials.gov/ct2/show/NCT00176592?term=Glatiramer&rank=31 [Accessed 2 February 2010]